Awards

Introducing the Pharmaceutical Technology Excellence Awards 2024

The 2024 Pharmaceutical Technology Excellence Awards are open for submissions. Download our Research Guide for more details.

The Pharmaceutical Technology Excellence Awards celebrate the greatest achievements and innovations in the industry. The programme provides a platform to recognize the people and companies that are driving change.

Our programme is designed to highlight excellence within the sector assessing a variety of corporate activities including deals, business projects and company initiatives – both internal and within the community.

How to take part in the Excellence Awards

To learn how to enter your organisation for the awards, please download the Research Guide. This comprehensive guide provides details on the necessary submission information, and the process for submitting information to us.

Download our Research Guide for more information

How the Excellence Awards work

Companies and institutions undergo evaluation based on their performance in 12 key Areas of Excellence, supported by evidence from both our research and ranking submission process.

  • Business Expansion
  • Diversity
  • Environmental
  • Financing
  • Innovation
  • Investments
  • M&A
  • Marketing
  • Product Launches
  • Research and Development
  • Safety
  • Social

For comprehensive details on our methodology and scoring system, please download the Research Guide.

Making the most of your award win

Participating in the Excellence Awards offers your company numerous benefits, including the ability to showcase your achievements to the market and attract new prospective clients.

For a comprehensive understanding of the benefits, the scale of our audience, and the marketing packages available, please download the Research Guide or contact Tina Ross at tina.ross@globaldata.com.

Frequently-Asked-Questions (FAQ)

Are there any associated costs with the awards?
While there is no fee for submitting information, we offer a variety of packages to enhance your exposure and promote your success to our audience. For details, please contact Tina Ross at tina.ross@globaldata.com.

What sort of projects can I submit as case studies?
Ensure that case studies align with one of our 12 Areas of Excellence. Refer to the examples provided under each category in the following section for guidance.

I’d like to submit a case study, but I’m unsure about the appropriate category for submission
Submission for a specific category is not mandatory; we will consider relevant case studies for all applicable categories.

How will our case study be used?
Case study details may be published with your ranking. If there are specific details you prefer not to be disclosed, please clearly state this in the description.

I would like to submit a long-term project as a case study. Is it eligible for consideration in this year’s research?
The project will be considered valid if a substantial amount of work has been undertaken during the research period.

Can I get an extension to the submission deadline?
​​​​​​​
Kindly email your extension request along with the desired duration to our research team.

Contact Us

For more information on the awards and our methodology, please contact Tina Ross at tina.ross@globaldata.com.

Go to article: Home | Enhancing therapy adherence with prodrugsGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: CytivaGo to article: NiproGo to article: Laboratorios Argenol Company InsightGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Avenga Company InsightGo to article: Lactalis IngredientsGo to article: BSP PharmaceuticalsGo to article: AlfatestLABGo to article: Alphial Company InsightGo to article: In DepthGo to article: Prodrugs and patents: Enhancing therapy adherence and reducing side effectsGo to article: Are PBMs to blame for high drug prices in the US?Go to article: Into the unknown: how quickly can vaccines be developed for Disease XGo to article: US negotiations for first round of drugs reveal $6bn in Medicare savings Go to article: Emerging microbiome market – unlocking new frontiers Go to article: Build or buy? Key considerations for in-house manufacturingGo to article: BiomeBank Company InsightGo to article: IMP Pharmaceutical ServicesGo to article: XylemGo to article: Sponsored SupplementsGo to article: Techniconsult Firenze Company InsightGo to article: PfanstiehlGo to article: Duoject Medical Systems Company InsightGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Zenatek Company InsightGo to article: BEA TechnologiesGo to article: Next issue